Respiratory Medicine
Volume 101, Issue 10 , Pages 2213-2216 , October 2007

DQA1*03011 allele: Protective or an adverse effect on the development of sarcoidosis; preliminary study

  • Anna Dubaniewicz

      Affiliations

    • Department of Pathophysiology, Medical University of Gdansk, 80-952 Gdansk, Debinki 7 Street, Poland
    • Corresponding Author InformationCorresponding author. Tel./fax: +48583491510
    • ,
  • Andrzej Dubaniewicz

      Affiliations

    • Ceynowy's Hospital, 84-200 Wejherowo, Jagalskiego 10 Street, Poland
    • ,
  • Ada Dubaniewicz

      Affiliations

    • Department of Clinical Anatomy, Medical University of Gdansk, 80-210 Gdansk, Debinki 1 Street, Poland
    • ,
  • Grażyna Moszkowska

      Affiliations

    • Department of Immunopathology, Medical University of Gdansk, 80-952 Gdansk, Debinki 7 Street, Poland

Received 9 January 2007 ,Accepted 3 June 2007.

References 

  1. American Thoracic Society. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:735–736
  2. Dubaniewicz A, Moszkowska G, Szczerkowska Z. Analysis of frequency of DRB1-DQB1 two-locus haplotypes in tuberculosis; preliminary report. Tuberculosis (Edinb). 2005;85:259–267
  3. Sharma SK, Balamurugan A, Pandey RM, Saha PK, Mehra NK. Human leukocyte antigen—–DR alleles influence the clinical course of pulmonary sarcoidosis in Asian Indians. Am J Respir Cell Mol Biol. 2003;29:225–231
  4. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 1997;56:1601–1605
  5. Ishihara M, Ohno S, Ishida T, et al. Molecular genetic studies of HLA class II alleles in sarcoidosis. Tissue Antigens. 1994;43:238–241
  6. Rutherford RM, Kearns M, Bourke M, Stevens F, Gilmartin JJ. HLA-DR2 predicts susceptibility and disease chronicity in Irish sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:191–198
  7. Boytim ML, Lyu SC, Jung R, Krensky AM, Clayberger C. Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65–79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug rapamycin. J Immunol. 1998;160:2215–2222
  8. Ling X, Kamangar S, Boytim ML, et al. Proliferating cell nuclear antigen as the cell cycle sensor for an HLA-derived peptide blocking T cell proliferation. J Immunol. 2000;164:6188–6192
  9. Boytim ML, Lilly P, Drouvalakis K, et al. A human class II MHC-derived peptide antagonizes phosphotidylinositol 3-kinase to block IL-2 signaling. J Clin Invest. 2000;105:1447–1453
  10. Dong C, Lyu SH, Krensky AM, Clayberger C. DQ65–79, a peptide derived from HLA class II, mimics p21 to block T cell proliferation. J Immunol. 2003;171:5064–5070
  11. Claus R, Werner H, Schulze HA, Walzel H, Friemel H. Are soluble monocyte-derived HLA class II molecules candidates for immunosuppressive activity?. Immunol Lett. 1990;26:203–210
  12. Nossner E, Goldberg JE, Naftzger C, Lyu SC, Clayberger C, Krensky AM. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J Exp Med. 1996;183:339–348
  13. Murphy B, Magee CC, Alexander SI, et al. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest. 1999;103:859–867

PII: S0954-6111(07)00256-9

doi: 10.1016/j.rmed.2007.06.004

Respiratory Medicine
Volume 101, Issue 10 , Pages 2213-2216 , October 2007

Article Tools